Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Twinlab

This article was originally published in The Tan Sheet

Executive Summary

Anticipates sales slowdown in the fourth quarter to $85 mil.-$90 mil., compared to $71.8 mil. in the year-ago period, the Ronkonkoma, N.Y.-based firm announces Dec. 1. Net income is expected to reach $8 mil.-$9 mil. in the quarter. Firm cites excess inventory from large purchase orders in the first half and "generally slower growth" of the supplement industry at retail. GNC's new pricing policy also may be contributing to the overall industry falloff; the manufacturer/ retailer implemented a strategy of discounting a rotating selection of products each month in response to mass and discount outlet competition ("The Tan Sheet" Aug. 10, p. 9). Also affecting Twinlab's results was a delay in the rollout of its new TruHerbs line because of packaging problems. The 45-SKU line was slated to launch in mass market outlets in late September ("The Tan Sheet" Aug. 10, p. 10). "These issues are expected to continue into 1999," Twinlab says, predicting flat first quarter sales and income. Twinlab full-year sales are projected to reach $338.4 mil., up 47.4%, on net income of $37.1 mil., up 50.8%

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS089169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel